Antibody Drug Conjugates Market Analysis

Antibody Drug Conjugates Market Analysis

To get key market trends

  Download Free Sample

By product type, the antibody drug conjugates market is classified into Adcetris, Perjeta, Kadcyla and other product type. Kadcyla segment accounted for 32.5% of the market share in 2022. Kadcyla specifically targets cancer cells that overexpress the HER2 protein, delivering a potent chemotherapy agent directly to the tumor site. This targeted approach increases treatment efficacy while minimizing harm to healthy cells, resulting in improved patient outcomes and reduced side effects compared to traditional chemotherapy. Therefore, owing to such benefits, the drug has shown significant success in treating HER2-positive breast cancer and has been approved for use in several countries.
 

Based on technology, the antibody drug conjugates market is segmented into cleavable linker, non-cleavable linker and linkerless. The cleavable linker is expected to register over USD 14.3 billion by 2032. Cleavable linker technology is one of the significant advancements in antibody drug conjugates that enables to release the cytotoxic payload specifically within cancer cells, thereby enhancing treatment efficacy. Cleavable linker technology allows for precise delivery of potent drugs to the target site, ensuring that the cytotoxic payload is released in a controlled manner, thereby maximizing its impact on cancer cells while sparing healthy tissues.
 

By application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovary cancer, lung cancer and other applications. The breast cancer segment is expected to grow at 15.3% by 2032. ADCs offer a targeted approach by utilizing monoclonal antibodies to specifically recognize and bind to cancer cells expressing certain proteins, such as HER2. This targeted binding enables the delivery of potent cytotoxic drugs directly to the cancer cells, resulting in enhanced efficacy and reduced toxicity. The use of ADCs in breast cancer treatment has shown promising results, including improved response rates, prolonged progression-free survival and better overall patient outcomes.
 

The target type in antibody drug conjugates market is divided into HER2 antibodies, CD30 antibodies, HER2 Antibodies and other target type. HER2 antibodies accounted for USD 3.3 billion market revenue in 2022. HER2-positive cancers, including breast and gastric cancers are characterized by overexpression of the HER2 protein. ADCs designed to target HER2 antibodies allow for precise binding and delivery of potent cytotoxic drugs to cancer cells that overexpress HER2. They serve as a crucial component in ADCs, facilitating selective targeting and payload delivery making them a valuable tool in the development of targeted cancer therapies. Furthermore, various ongoing clinical trials of ADC for breast cancer and other solid tumors is expected to increase the potential of ADCs to provide more promising treatment.
 

North America antibody drug conjugates market accounted for over 49.5% business share in 2022. The increasing prevalence of cancer and growing demand for targeted therapies is expected to boost the market gains in the North America region. Also, advanced healthcare infrastructure, presence of key players and strong R&D facilities have contributed to the significant adoption and commercial success of ADCs, thereby augmenting the market progression in the North America region.